Related Experiment Video
Updated: Nov 18, 2025
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma
Sitansu S Nanda1, Md Imran Hossain1, Heongkyu Ju2
1Department of Chemistry, Myongji University, Yongin, 03674, South Korea.
Background:
Glycogen syntheis kinase (GSK-3) inhibitors are novel therapeutic agents for treating various types of cancer, such as breast, lung, and gastric cancer. No pathological changes have been found by the morphological examination of GSK-3.
Objectives:
This review describes recent procedures using GSK-3 inhibitors, primarily in treating colon carcinoma. Furthermore, it also explains the mechanism of action of different GSK-3 inhibitors in treating various types of cancers and proposes some additional mechanisms may be useful for further research on GSK-3 inhibitors for cancers, including colon carcinoma.
Results:
The majority of the cancerous and pre-cancerous lesions are stimulated by the transformation of membrane-bound arachidonic acid (AA) to eicosanoids, a transformation that promotes for the viability, proliferation, and spread of cancer. GSK-3 inhibitors can reinstate hostility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) responsiveness in gastric adenocarcinoma cells. GSK-3, the final enzyme in glycogen synthesis, is a serine/threonine kinase that phosphorylates varied sequences that are more than a hundred in number, within proteins in an array of heterogeneous pathways. It is an essential module of an exceptionally large number of cellular processes, playing a fundamental role in many metabolic processes and diseases. Many patients diagnosed with colon cancer achieve long-term remission with outstanding survival through the GSK-3 inhibitors.
Conclusion:
Prior to the extensive application of these proposed mechanisms of GSK-3 inhibitor, further evaluation and clinical studies are needed. Only after the completion of appropriate clinical studies and morphological examinations, would extensive application be apprpriate.
Insights
Glycogen synthesis kinase (GSK-3) inhibitors show promise as cancer therapeutics, particularly for colon carcinoma. Further clinical studies are needed to confirm their efficacy and safety before widespread application.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Glycogen synthesis kinase (GSK-3) inhibitors are emerging as novel therapeutic agents for various cancers, including breast, lung, and gastric types.
- Morphological examinations have not revealed any pathological changes associated with GSK-3.
Purpose of the Study:
- This review focuses on recent advancements in using GSK-3 inhibitors for colon carcinoma treatment.
- It also elucidates the mechanisms of action of various GSK-3 inhibitors in different cancers.
- Additionally, it proposes novel mechanisms for future research on GSK-3 inhibitors in cancer therapy.
Main Methods:
- Literature review of recent procedures and mechanisms of GSK-3 inhibitors in cancer treatment.
- Analysis of the role of GSK-3 in cellular processes and disease pathways.
- Examination of the impact of GSK-3 inhibitors on cancer cell responsiveness to apoptosis-inducing ligands.
Main Results:
- GSK-3 inhibitors can restore sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in gastric adenocarcinoma cells.
- GSK-3, a serine/threonine kinase, plays a crucial role in numerous cellular pathways and metabolic processes.
- Many colon cancer patients treated with GSK-3 inhibitors have achieved long-term remission and survival.
Conclusions:
- Further clinical studies and morphological evaluations are essential before the widespread application of proposed GSK-3 inhibitor mechanisms.
- Comprehensive evaluation is required to ensure the safety and efficacy of these novel cancer therapies.
